CATB Key Statistics, Chart & Performance
The current stock price of CATB is 8.54 null. In the past month the price increased by 3.89%. In the past year, price decreased by -78.07%.
CATB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About CATB
Company Profile
Catabasis Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 20 full-time employees. The company went IPO on 2015-06-25. Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The firm is focused on development and commercialization of therapeutics. The firm's lead product candidate is QLS-215. QLS-215 is a monoclonal antibody designed to inhibit plasma kallikrein for the treatment of hereditary angioedema, or HAE, a rare, debilitating and life-threatening disease. Plasma kallikrein is a critical component of HAE that causes pathologic vascular permeability, vasodilation and excessive tissue swelling. The firm is in the preclinical development for QLS-215 and to initiate a Phase I a clinical trial.
Company Info
Catabasis Pharma
100 High Street, 28th Floor
Boston MASSACHUSETTS 02110 US
CEO: Jill C. Milne
Employees: 20
Phone: 16173491971.0
Catabasis Pharma / CATB FAQ
What does CATB do?
Catabasis Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 20 full-time employees. The company went IPO on 2015-06-25. Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The firm is focused on development and commercialization of therapeutics. The firm's lead product candidate is QLS-215. QLS-215 is a monoclonal antibody designed to inhibit plasma kallikrein for the treatment of hereditary angioedema, or HAE, a rare, debilitating and life-threatening disease. Plasma kallikrein is a critical component of HAE that causes pathologic vascular permeability, vasodilation and excessive tissue swelling. The firm is in the preclinical development for QLS-215 and to initiate a Phase I a clinical trial.
Can you provide the latest stock price for Catabasis Pharma?
The current stock price of CATB is 8.54 null. The price decreased by -6.97% in the last trading session.
Does CATB stock pay dividends?
CATB does not pay a dividend.
What is the ChartMill rating of Catabasis Pharma stock?
CATB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of CATB stock?
Catabasis Pharma (CATB) operates in the Health Care sector and the Biotechnology industry.
What is the ownership structure of Catabasis Pharma (CATB)?
You can find the ownership structure of Catabasis Pharma (CATB) on the Ownership tab.
CATB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CATB. When comparing the yearly performance of all stocks, CATB is a bad performer in the overall market: 99.04% of all stocks are doing better.
CATB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CATB. The financial health of CATB is average, but there are quite some concerns on its profitability.
CATB Financial Highlights
Over the last trailing twelve months CATB reported a non-GAAP Earnings per Share(EPS) of -5.9. The EPS decreased by -175.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -140.05% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CATB Forecast & Estimates
4 analysts have analysed CATB and the average price target is 24.23 null. This implies a price increase of 183.67% is expected in the next year compared to the current price of 8.54.